GW572016 For Treatment Of Refractory Metastatic Breast Cancer

Update Il y a 3 ans
Reference: NCT00062686

Woman Man


This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.

Inclusion criteria

  • Neoplasms, Breast